Document:

Sydney Acquisitions ULC

Millennium Pharmaceuticals, Inc.

40 Lansdowne Street

Cambridge, Massachusetts 02139

DELIVERED AND                                                                                                                                                October
17, 2006

BY FACSIMILE (604-530-0976)

AnorMED Inc.

200 — 20353 64th Avenue

Langley, British Columbia

V2Y 1N5

	
  Attention:

  	
   

  	
  Kenneth Galbraith

  
	
   

  	
   

  	
  Chairman and Interim Chief Executive Officer

  
	
   

  	
   

  	
   

  
	
  Re:

  	
  Support Agreement dated as of September 26, 2006
  between AnorMED Inc.

  
	
   

  	
  (“AnorMED”) and Millennium Pharmaceuticals, Inc.

  
				

 

We are writing with respect to the above-captioned Support
Agreement.  Capitalized terms used but
not defined in this letter have the meanings assigned to them in such Support
Agreement.

Following our discussions and negotiations, this letter is written to
set out our mutual agreement pursuant to Section 8.1(a) of the Support
Agreement that the Support Agreement will terminate and be of no further force
or effect, effective at 12:01 a.m. (Vancouver time) today (other than
Section 7.4 of the Support Agreement which remains in full force and effect).  We acknowledge AnorMED will be entering into
a support agreement with Genzyme Corporation and Dematal Corp. and AnorMED’s
intention to recommend to its shareholders the acceptance of the revised offer
to be made thereunder.

In consideration of the foregoing agreement between the parties and
other good and valuable consideration, the sufficiency of which is
acknowledged:

1.                                       AnorMED agrees to pay today the amount of US$19.5
million to, or as directed by, the Parent; and

2.                                       except
for the payments contemplated by paragraph 1 above, AnorMED and the Offeror
agree that neither party hereto shall have any obligations to make any other
payments to the other party, under Section 6.2 of the Support Agreement or
otherwise, and each of AnorMED and the Offeror, on behalf of itself and each of
its parents (existing as of the date hereof), Affiliates (existing as of the
date hereof) and Subsidiaries, and their respective directors, officers,
employees, agents, advisers and attorneys, and their respective successors and
assigns (collectively, the “Releasing Parties”), hereby irrevocably
releases, acquits, forever discharges and covenants not to commence a legal
action against the other, and each of its parents (existing as of the date
hereof) , Affiliates 

 

                                                (existing
as of the date hereof) and Subsidiaries, and their respective past and present
directors, officers, employees, agents, advisers and attorneys, and their
respective successors and assigns (collectively, the “Released Parties”),
of and from any and all claims, demands and causes of action that the Releasing
Parties, severally or jointly with others, had, has or may have against the
Released Parties, or any of them by reason of, arising out of or relating to
any aspect of the Support Agreement (collectively, the “Released Claims”),
including without limitation any claim relating to any intentional or willful
breach of the Support Agreement. 
Notwithstanding the foregoing, the Released Claims shall not include any
claims, demands or causes of action that arise out of or relate to the
Confidentiality Agreement or this Termination Agreement or which a party had,
has or may have against Genzyme Corporation or its Affiliates (existing as of
the date hereof) or Subsidiaries (existing as of the date hereof) or any of their
respective directors, officers, employees, agents, advisers or attorneys,
whether or not any of them is or becomes a successor or assign of a Released
Party.

For greater certainty, the parties hereto agree that the
Confidentiality Agreement remains in full force and effect as of the date
hereof.

Each of the parties hereby confirm to the other the same
representations and warranties as to their power and authority to enter into
and the binding nature of this agreement as if the representations and warranties
given under Sections 1, 2 and 3 of Schedule B and Sections 1, 3
and 4 of Schedule C respectively of the Support Agreement applied to the
agreement reflected in this letter.  The
parties also confirm their intention that Section 1.8 (governing law), Section 1.9
(attornment), Section 9.4 (enurement) and Section 9.9 (counterpart
execution) of the Support Agreement will apply to the agreement reflected in
this letter.

 2
 

 

 

We trust the foregoing adequately confirms our agreement with respect
to the termination of our Support Agreement. 
Could you please sign and return a copy of this letter to confirm your
agreement.

Yours truly,

Sydney Acquisitions ULC

and Millennium Pharmaceuticals, Inc.

/s/ Deborah Dunsire

Deborah Dunsire, M.D.

President and Chief Executive Officer

	
   

  	
   

  	
  Acknowledged and agreed this 17th day of October, 2006:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  AnorMED Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  /s/ Kenneth Galbraith

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Kenneth Galbraith, Chairman and Interim Chief
  Executive Officer

  
	
   

  	
   

  	
   

  
	
  cc

  	
  McCarthy Tétrault LLP

  	
   

  
	
   

  	
  Attention: Tim McCafferty

  	
   

  
	
   

  	
  (facsimile: 604-622-5780)

  	
   

  
	
   

  	
   

  	
   

  
	
  cc

  	
  Farris Vaughan Wills & Murphy LLP

  	
   

  
	
   

  	
  Attention: R. Hector MacKay-Dunn, Q.C.

  	
   

  
	
   

  	
  (facsimile: 604-661-9349)

  	
   

  
	
   

  	
   

  	
   

  
	
  cc

  	
  Dorsey & Whitney LLP

  	
   

  
	
   

  	
  Attention: Daniel Miller

  	
   

  
	
   

  	
  (facsimile: 604-687-8504)

  	
   

  

 

 3Sydney
Acquisitions ULC

Millennium Pharmaceuticals, Inc.

40 Lansdowne Street

Cambridge, Massachusetts

02139

DELIVERED AND                                                                                                                                October
17, 2006

BY FACSIMILE (212-521-2245)

Baker Bros.
Investments, L.P.

Baker Bros. Investments II, L.P.

Baker Biotech Fund I, L.P.

14159, L.P.

Baker/Tisch Investments, L.P.

Baker Brothers Life Sciences L.P.

(each person a “Shareholder” and 

collectively the “Shareholders”)

c/o Baker Brothers Investments

667 Madison Avenue, 17th Floor

New York, NY 10021

	
  Re:

  	
   

  	
  Shareholder Support Agreement dated as of September
  26, 2006 between the Shareholders and

  
	
   

  	
   

  	
  Millennium Pharmaceuticals, Inc. (the “Shareholder
  Support Agreement”)

  

 

We are writing
with respect to the above-captioned Shareholder Support Agreement.  Capitalized terms used but not defined in
this letter have the meanings assigned to them in the Shareholder Support
Agreement.

This letter is written to set out our mutual agreement pursuant to
Section 5.3 of the Shareholder Support Agreement that the Shareholder
Support Agreement will terminate and be of no further force or effect,
effective at 12:01 a.m. (Vancouver time) today. 
We acknowledge that the Shareholders will enter into a shareholder
support agreement with Genzyme Corporation and Dematal Corp.

Each of the parties hereby confirm to the other the same
representations and warranties as to their power and authority to enter into
and the binding nature of this agreement as if the representations and
warranties given under Sections 4.1(a) and (c) and Sections 4.2(a), (b) and (c)
of the Shareholder Support Agreement apply to the agreement reflected in this
letter.  The parties also confirm their
intention that Section 6.8 (governing law), Section 6.9 (attornment) and
Section 6.17 (counterpart execution) of the Shareholder Support Agreement will
apply to the agreement reflected in this letter.

[Remainder of page intentionally
left blank]

 

 

We trust the foregoing adequately confirms our agreement with respect
to the termination of our Shareholder Support Agreement.  Could you please sign and return a copy of
this letter to confirm your agreement.

Yours truly,

	
  Sydney Acquisitions ULC

  	
   

  	
   

  
	
  and Millennium Pharmaceuticals, Inc.

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  /s/ Marsha Fanucci

  	
   

  	
   

  
	
  Name: Marsha Fanucci

  	
   

  	
   

  
	
  Title: Chief Financial Officer

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Acknowledged and agreed this 17th day of October, 2006:

  
	
   

  	
   

  	
   

  
	
   

  	
  BAKER
  BIOTECH FUND I, L.P.

  
	
   

  	
  By:

  	
  Baker/Tisch Capital, L.P., its general partner

  
	
   

  	
  By:

  	
  Baker/Tisch Capital (GP), LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Felix Baker

  
	
   

  	
   

  	
  Name: Felix Baker, Ph.D

  
	
   

  	
   

  	
  Title: Managing Member

  
	
   

  	
   

  	
   

  
	
   

  	
  14159, L.P.

  
	
   

  	
  By: 

  	
  14159 Capital, L.P., its general partner

  
	
   

  	
  By: 

  	
  14159 Capital (GP), LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Felix Baker

  
	
   

  	
   

  	
  Name: Felix Baker, Ph.D

  
	
   

  	
   

  	
  Title: Managing Member

  
	
   

  	
   

  	
   

  
	
   

  	
  BAKER BROTHERS LIFE SCIENCES, L.P.

  
	
   

  	
  By: 

  	
  Baker Brothers Life Sciences Capital, L.P., its
  general partner

  
	
   

  	
  By: 

  	
  Baker Brothers Life Sciences Capital, (GP) LLC, its
  general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Felix Baker

  
	
   

  	
   

  	
  Name: Felix Baker, Ph.D

  
	
   

  	
   

  	
  Title: Managing Member

  

 

 

 

	
  

  	
  BAKER/TISCH
  INVESTMENTS, L.P.

  
	
   

  	
  By: 

  	
  Baker/Tisch Capital, L.P., its general partner

  
	
   

  	
  By: 

  	
  Baker/Tisch Capital, (GP), LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Felix Baker

  
	
   

  	
   

  	
  Name: Felix Baker, Ph.D

  
	
   

  	
   

  	
  Title: Managing Member

  
	
   

  	
   

  	
   

  
	
   

  	
  BAKER
  BROS. INVESTMENTS, L.P.

  
	
   

  	
  By: 

  	
  Baker Bros. Capital, L.P., its general partner

  
	
   

  	
  By: 

  	
  Baker Bros. Capital (GP), LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Felix Baker

  
	
   

  	
   

  	
  Name: Felix Baker, Ph.D

  
	
   

  	
   

  	
  Title: Managing Member

  
	
   

  	
   

  	
   

  
	
   

  	
  BAKER BROS. INVESTMENTS II, L.P.

  
	
   

  	
  By: 

  	
  Baker Bros. Capital, L.P., its general partner

  
	
   

  	
  By: 

  	
  Baker Bros. Capital (GP), LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Felix Baker

  
	
   

  	
   

  	
  Name: Felix Baker, Ph.D

  
	
   

  	
   

  	
  Title: Managing Member

  

 

	
  cc:

  	
  McCarthy Tetrault LLP

  	
   

  	
   

  
	
   

  	
  Attention: Tim McCafferty

  	
   

  	
   

  
	
   

  	
  (facsimile: 
  604-622-5780)

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  cc:

  	
  Davies Ward Phillips & Vineberg LLP

  	
   

  	
   

  
	
   

  	
  Attention: 
  Berl Nadler

  	
   

  	
   

  
	
   

  	
  (facsimile: 
  416-863-0871)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]